HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bloomgarden, Z. T. Search for Related Content PubMed PubMed Citation Articles by Bloomgarden, Z. T. Social Bookmarking                What's this?

Exploring Treatment Strategies for Type 2 Diabetes

Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is affiliated with the Division of Endocrinology, Mount Sinai School of Medicine, New York, New York

Abbreviations: ADA, American Diabetes Association • ADOPT, A Diabetes Outcome Progression Trial • DPP, dipeptidyl peptidase • GIP, glucose-dependent insulinotropic peptide • GLP, glucagon-like peptide • UKPDS, UK Prospective Diabetes Study

The first 300 words of the full text of this article appear below.

Perspectives on the News commentaries are now part of a new, free monthly CME activity. The Mount Sinai School of Medicine, New York, New York, is designating this activity for 2.0 AMA PRA Category 1 credits. If you wish to participate, review this article and visit www.diabetes.procampus.net to complete a posttest and receive a certificate. The Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This is the second in a series of articles based on presentations at the American Diabetes Association's 67th Scientific Sessions in June 2007, in Chicago, discussing approaches to the treatment of type 2 diabetes, contrasting the use of older therapies with the use of new agents to lower blood glucose levels.

At a symposium on the use of insulin in treatment of type 2 diabetes, Rury Holman (Oxford, U.K.) reviewed the findings of the UK Prospective Diabetes Study (UKPDS) and A Diabetes Outcome Progression Trial (ADOPT) in terms of the performance of metformin, sulfonylureas, thiazolidinediones, and insulin.

Among the newly diagnosed diabetic individuals entering the UKPDS, mean A1C fell from 9 to 7% with diet modification. At 1 year, mean A1C was 6% with insulin, sulfonylurea, and metformin treatment. After 3, 6, and 9 years in UKPDS, however, only 40, 40, and 30% of individuals receiving insulin maintained A1C <7%. Among those on sulfonylurea monotherapy, 45% had A1C <7% at 3 years, but the proportions decreased to 30 and 20% at 6 and 9 years, respectively, with 45, 35, and 15% of those receiving metformin monotherapy maintaining A1C <7% at these times. Holman characterized this inexorable increase as one of the principal challenges of glycemic treatment of individuals with type 2 diabetes. Interestingly, the widely used sulfonylurea glyburide was less . . . [Full Text of this Article]

Combination oral hypoglycemic treatment approaches

Insulin for treatment of type 2 diabetes: pro

Insulin for treatment of type 2 diabetes: con

Incretin mimetics for type 2 diabetes

DPP-4 inhibitors for type 2 diabetes

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H.-S. Chen, T.-E. Wu, T.-S. Jap, L.-C. Hsiao, S.-H. Lee, and H.-D. Lin Beneficial Effects of Insulin on Glycemic Control and {beta}-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe Hyperglycemia After Short-Term Intensive Insulin Therapy Diabetes Care, October 1, 2008; 31(10): 1927 - 1932. [Abstract] [Full Text] [PDF]